Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149537 | 1.00 | KDM4E (0.46) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| SCHEMBL29666411 | 1.00 | KDM4E (0.46) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL10524097 | 0.98 | KDM4E (0.45) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| Formaldehyde SCHEMBL27640099 | 0.94 | KDM4E (0.42) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| Biphenyl SCHEMBL28365892 | 0.92 | NPC1 (0.44) | KDM4EEGFRGPR3ALDH1A1GLA | |
| SCHEMBL20163588 | 0.88 | EGFR (0.38) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| SCHEMBL29520469 | 0.80 | CYP1A2 (0.44) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| Valine SCHEMBL9998032 | 0.76 | SLC7A5 (0.42) | KDM4EALDH1A1CYP1A2SMN1; SMN2RAB9A | |
| SCHEMBL30198446 | 0.75 | CYP1A2 (0.60) | KDM4EEGFRGPR3ALDH1A1MAPT | |
| SCHEMBL30527184 | 0.75 | CYP1A2 (0.60) | KDM4EEGFRGPR3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676600-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF | Deliver Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| WO-2024186579-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF | DELIVER THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| CN-112533911-B | Compound and organic light emitting device comprising the same | 株式会社LG化学 | 2023-12-26 | — | — | CN | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4142707-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4093400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | The Trustees of Princeton University (US) | 2022-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KDM4E 3221/4885EGFR 262/4885GPR3 1366/4885 |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KDM4E 3221/4885EGFR 262/4885GPR3 1366/4885 |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KDM4E 3220/4885EGFR 180/4885GPR3 1429/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KDM4E 3220/4885EGFR 180/4885GPR3 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.